Dr. Senderowicz was appointed as a director of Puma Biotechnology on August 11, 2015. Dr. Senderowicz has been Senior Advisor of Constellation Pharmaceuticals, Inc., a private clinical-stage biopharmaceutical company focusing on the development of novel tumor-targeted and immuno-oncology therapies, since June 2020 and served as its Senior Vice President and Chief Medical Officer from July 2017 until June 2020.
Prior to joining Constellation, Dr Senderowicz served as Senior Vice President and Chief Medical Officer at Cerulean Pharma, Inc., a public clinical-stage company developing nano-particle conjugates, from September 2015 to June 2017. Prior to joining Cerulean, Dr. Senderowicz served as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs from August 2014 to February 2015, and Clinical and Regulatory Strategy Officer from February 2015 to April 2015 of Ignyta, Inc., a public precision oncology biotechnology company.
Previously, Dr. Senderowicz was Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. Prior to Sanofi, he was Chief Medical Officer and Vice President, Medical Development at Tokai Pharmaceuticals, Inc. from August 2012 to March 2013. From August 2008 to March 2012, he held positions of increasing responsibility, including Senior Medical Director, Oncology Clinical Development, at AstraZeneca. Before his tenure at AstraZeneca, Dr. Senderowicz spent almost four years in a variety of leadership positions at the U.S. Food and Drug Administration Division of Oncology Drug Products in the Center for Drug Evaluation and Research. Prior to his work with the FDA, he held a variety of clinical and research positions, including Coordinator of the Prostate Cancer Drug Development Clinic and Investigator and Chief, Molecular Therapeutics Unit, with the National Cancer Institute/National Institutes of Health.
Dr. Senderowicz holds both an M.D. and an Instructor of Pharmacology degree from the School of Medicine at the Universidad de Buenos Aires in Argentina. Dr. Senderowicz was selected as a director because of his extensive clinical and regulatory background and his significant experience in the life sciences industry.
What is Adrian Senderowicz's net worth?
The estimated net worth of Adrian Senderowicz is at least $203.58 thousand as of June 13th, 2025. Senderowicz owns 27,000 shares of Puma Biotechnology stock worth more than $203,580 as of April 28th. This net worth approximation does not reflect any other investments that Senderowicz may own. Learn More about Adrian Senderowicz's net worth.
How do I contact Adrian Senderowicz?
Has Adrian Senderowicz been buying or selling shares of Puma Biotechnology?
Adrian Senderowicz has not been actively trading shares of Puma Biotechnology over the course of the past ninety days. Most recently, Adrian Senderowicz sold 27,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a transaction totalling $91,800.00. Following the completion of the sale, the director now directly owns 27,000 shares of the company's stock, valued at $91,800. Learn More on Adrian Senderowicz's trading history.
Who are Puma Biotechnology's active insiders?
Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 1/7/2026.
